25+ years of clinical use
May help mitigate risk of MARCE in comorbid patients1
Iso-osmolar and isotonic
Reducing vascular fluid shift and impact of differences in osmotic pressure2,3
May help reduce costs
Lower hospitalization costs due to shortened length of stay4,5
More than 1 in 7 adults in the US are estimated to have CKD, and most don't know it.6 34.2 million Americans - just over 1 in 10 - have diabetes.7 By 2060, 1 in 4 people in the US will be aged 65+, with the number over 85 years expected to nearly triple.8
Appropriate selection of contrast media for necessary diagnostic or interventional procedure imaging in at risk patients should be considered to help mitigate the risk of adverse events.9 Visipaque is an iodinated iso-osmolar, isotonic contrast agent indicated for multiple intra-arterial and intravenous procedures in adults and pediatric patients.
Interventional, structural, or endovascular procedures (e.g. Transcatheter Aortic Valve Implantation (TAVI), interventions for Chronic Total Occlusion (CTO), Percutaneous Coronary Intervention (PCI)) may need to use higher volumes of iodinated contrast media, potentially leading to greater incidence of acute kidney injury (AKI). Reducing the frequency of adverse reactions such as AKI, major adverse renal cardiovascular event (MARCE), and acute AEs has therefore been a driving force in the development of these diagnostic agents since their initial introduction.9,10
Visipaque is an isotonic, third-generation agent with a dimeric molecular structure developed to further improve the safety profile of iodinated contrast agents.11,12 It is iso-osmolar to blood with the aim of counteracting major fluid shifts across membranes and limiting discomfort.12-14 It is also formulated with balanced electrolytes to help minimize effects on cardiac contractile force/fibrillatory
propensity.12-14 While 'low' osmolar agents form the mainstay in the general population of patients undergoing endovascular diagnostic or interventional procedures, Visipaque may be selected for more complex procedures in patients considered at risk for cardiovascular or renal adverse outcomes.1,11
Introducing the flip top cap on our +PLUSPAK™ polymer bottles. This packaging facilitates opening the cap and is an improvement on the ring pull design, with a reduced risk of injury15. This new design also helps reduce costs and environmental impact with less storage space needed and lower disposal costs.16-18 It helps to streamline processes and traceability through color coding, triple-tracking stickers, a 2D DataMatrix, and an integrated hanger with a label easy to read even when inverted.
When compared to total interventional procedure cost, contrast media is inexpensive but contrast-associated acute kidney injury (CA-AKI) and contrast media-related adverse events may increase the use of health care resources and cost of care.19 Given the growth of vulnerable patient populations, it is important to identify clinical practices that reduce the incidence and associated costs of MARCE.5
According to a study conducted to determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the US, moving on to an IOCM-only strategy may yield potential cost savings associated with MARCE to US hospitals where coronary and peripheral procedures are performed.5
Enhancing patient comfort during peripheral endovascular procedures is important for both patients and efficiency, as movement during scanning may necessitate studies being repeated or prolonged. 13, 30-31
A benefit of iso-osmolar Visipaque when compared with pooled LOCMs is the reduction in discomfort associated in arteriography.12 According to the ACR, iso-osmolar CM “...are associated with the least amount of vasospasm and the least peripheral discomfort for peripheral angiograms”.32
In the interventional cardiology setting, use of iso-osmolar Visipaque is supported by:
• Robust randomized controlled trials20-23
• Meta-analyses of intra-arterial studies24-26
• Registry and real-world data analysis outcomes1, 27-29
Contrast-enhanced CT is important to every step of a cancer patient’s journey, from diagnosis and staging to monitoring and follow-up.33 Cancer patients may be susceptible to the adverse renal effects of iodinated CM as they are exposed to multiple nephrotoxic insults, predisposed to dehydration and require many CT scans.33-35 CI-AKI and CKD are highly prevalent.36
Visipaque can help cancer patients by:
• delivering diagnostic accuracy through enabling valuable contrast-enhanced CT in patients with renal impairment37
• addressing renal complications considering vulnerable patients with multiple risk factors37-39
• minimising contrast-associated pain protecting patient comfort and care40-41
Learn more about supporting resources for contrast media?
Educational programs
Webinar: Acute Kidney Injury - Complications in the Cardiac Cath Lab
Contrast-associated acute kidney injury (CA-AKI) is a challenge that may be encountered in the cardiac catheterization lab. In this on-demand webinar, Dr. Arnold Seto, Cardiac Cath Lab Director, Long Beach VA, and Director of Interventional Cardiology Research at University of California, Irvine, discusses the increasing incidence with comorbidities and complex procedures. He talks about the implications of AKI as well as mitigation strategies. Dr. Seto also shares emerging data on AKI in COVID-19 patients.
Watch now